[go: up one dir, main page]

MX2022010228A - Cd137 binding molecules and uses thereof. - Google Patents

Cd137 binding molecules and uses thereof.

Info

Publication number
MX2022010228A
MX2022010228A MX2022010228A MX2022010228A MX2022010228A MX 2022010228 A MX2022010228 A MX 2022010228A MX 2022010228 A MX2022010228 A MX 2022010228A MX 2022010228 A MX2022010228 A MX 2022010228A MX 2022010228 A MX2022010228 A MX 2022010228A
Authority
MX
Mexico
Prior art keywords
epitope
binding
binding molecules
molecules
sites specific
Prior art date
Application number
MX2022010228A
Other languages
Spanish (es)
Inventor
Kalpana Shah
Paul A Moore
Ezio Bonvini
Gundo Diedrich
Alexey Yevgenyevich Berezhnoy
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2022010228A publication Critical patent/MX2022010228A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137, including antibodies, and molecules comprising epitope-binding fragments thereof The invention is further directed to multispecific binding molecules comprising one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen ("TA") (e.g, a "CD137 x TA Binding Molecule").
MX2022010228A 2020-02-21 2021-02-16 Cd137 binding molecules and uses thereof. MX2022010228A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062980000P 2020-02-21 2020-02-21
US202063104685P 2020-10-23 2020-10-23
US202163147565P 2021-02-09 2021-02-09
PCT/US2021/018177 WO2021167885A1 (en) 2020-02-21 2021-02-16 Cd137 binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2022010228A true MX2022010228A (en) 2022-09-19

Family

ID=77391579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010228A MX2022010228A (en) 2020-02-21 2021-02-16 Cd137 binding molecules and uses thereof.

Country Status (13)

Country Link
US (1) US12435155B2 (en)
EP (1) EP4106813A4 (en)
JP (2) JP7745556B2 (en)
KR (1) KR20220144821A (en)
CN (1) CN115279403A (en)
AU (1) AU2021224787A1 (en)
BR (1) BR112022015656A2 (en)
CA (1) CA3170330A1 (en)
IL (1) IL295434A (en)
MX (1) MX2022010228A (en)
TW (2) TW202542198A (en)
WO (1) WO2021167885A1 (en)
ZA (1) ZA202210020B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311771A (en) * 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against PD-L1 and CD137 in combination

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
PL204629B1 (en) 1999-06-25 2010-01-29 Genentech Inc Humanized antibodies of anti-ERBB2 and treatment with antibodies of anti-ERBB2
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (en) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimeric, single chain, tandem Fv antibodies
EP1519956B1 (en) 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
CA2490399C (en) 2002-06-19 2015-10-06 Raven Biotechnologies, Inc. Novel raag10 cell surface target and a family of antibodies recognizing that target
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7534604B2 (en) 2004-01-16 2009-05-19 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101363252B1 (en) 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Antibodies that bind to epha2 and methods of use thereof
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5231231B2 (en) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド Methods and compositions and uses for generating bioactive assemblies of increased complexity
EP1948680A4 (en) 2005-10-28 2010-01-13 Univ California METHODS AND COMPOUNDS FOR DETECTION AND ISOLATION OF LYMPHOMATIC CELLS
EP1959993B1 (en) 2005-12-16 2014-11-19 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
TWI421257B (en) 2006-03-10 2014-01-01 Wyeth Corp Anti-5t4 antibodies and uses thereof
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
DK2511301T3 (en) 2006-08-04 2018-03-12 Medimmune Ltd HUMAN ANTIBODIES AGAINST ERBB 2
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20100143245A1 (en) 2007-03-22 2010-06-10 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
JP2010190572A (en) 2007-06-01 2010-09-02 Sapporo Medical Univ Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
EP4331604B9 (en) * 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
JP2010249130A (en) 2009-03-27 2010-11-04 Sanden Corp Fluid machine
PE20120540A1 (en) 2009-05-27 2012-05-09 Hoffmann La Roche THREE-SPECIFIC OR TETRA-SPECIFIC ANTIBODIES
IN2012DN01663A (en) 2009-09-16 2015-06-05 Immunomedics Inc
CA2778714C (en) 2009-11-24 2018-02-27 Medimmune Limited Targeted binding agents against b7-h1
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TW201742925A (en) 2010-04-23 2017-12-16 建南德克公司 Production of heteromultimeric proteins
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
ES2667100T3 (en) 2010-08-02 2018-05-09 Macrogenics, Inc. Covalent Diabodies and Their Uses
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
RS57279B1 (en) 2011-04-25 2018-08-31 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
EP2709655B1 (en) 2011-05-17 2018-11-14 Trion Research GmbH Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
ES2732213T3 (en) 2011-05-21 2019-11-21 Macrogenics Inc Molecules that bind to CD3 capable of binding to human and non-human CD3
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
WO2013003647A2 (en) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc Methods for making multimeric polypeptides
KR101723273B1 (en) 2011-08-23 2017-04-04 로슈 글리카트 아게 Fc-free antibodies comprising two fab fragments and methods of use
JP2014533929A (en) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Bispecific binding molecules for 5T4 and CD3
HK1207398A1 (en) 2012-04-20 2016-01-29 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
CN104936621A (en) 2012-11-07 2015-09-23 辉瑞公司 Anti-iL-13 receptor alpha 2 antibodies and antibody-drug conjugates
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
HK1211299A1 (en) 2013-02-26 2016-05-20 罗切格利卡特公司 Bispecific t cell activating antigen binding molecules
WO2014137931A1 (en) 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
SG10201705245TA (en) 2013-03-14 2017-07-28 Macrogenics Inc Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
KR20160030936A (en) 2013-07-16 2016-03-21 제넨테크, 인크. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
WO2016022939A1 (en) 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
EP3722315A1 (en) 2014-09-05 2020-10-14 Janssen Pharmaceutica NV Cd123 binding agents and uses thereof
WO2016048938A1 (en) 2014-09-26 2016-03-31 Macrogenics, Inc. Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US20160257761A1 (en) 2015-03-06 2016-09-08 Macrogenics, Inc. HER2/neu-Specific Antibodies and Methods of Using Same
JP6694446B2 (en) 2015-05-08 2020-05-13 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and tumor antigens
SG10201906059VA (en) 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
EA201990578A1 (en) * 2016-09-23 2019-10-31 BINDING MOLECULES THAT MODULATE THE CELL BIOLOGICAL ACTIVITY
JP7128529B2 (en) 2016-12-23 2022-08-31 アールイーエムディー バイオセラピューティクス，インコーポレイテッド Immunization using an antibody that binds programmed death ligand-1 (PD-L1)
EP4389226A3 (en) * 2017-02-24 2024-12-18 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
MX2020010653A (en) 2018-04-09 2020-10-28 Origincell Therapeutics Co Ltd Anti-pd-l1 antibody and use thereof.
EP3830112A4 (en) * 2018-07-30 2022-12-21 University of Southern California Improving the efficacy and safety of adoptive cellular therapies
WO2020041404A1 (en) 2018-08-23 2020-02-27 Macrogenics, Inc. Pd-l1-binding molecules and use of the same for the treatment of disease
IL294207A (en) 2019-12-23 2022-08-01 Macrogenics Inc Cancer treatment

Also Published As

Publication number Publication date
CA3170330A1 (en) 2021-08-26
TW202542198A (en) 2025-11-01
CN115279403A (en) 2022-11-01
IL295434A (en) 2022-10-01
EP4106813A1 (en) 2022-12-28
ZA202210020B (en) 2023-06-28
KR20220144821A (en) 2022-10-27
BR112022015656A2 (en) 2022-09-27
AU2021224787A1 (en) 2022-10-06
TW202144398A (en) 2021-12-01
JP2023514167A (en) 2023-04-05
JP7745556B2 (en) 2025-09-29
JP2025186381A (en) 2025-12-23
WO2021167885A1 (en) 2021-08-26
EP4106813A4 (en) 2024-03-27
TWI889761B (en) 2025-07-11
US20230094162A1 (en) 2023-03-30
US12435155B2 (en) 2025-10-07

Similar Documents

Publication Publication Date Title
MX2019009967A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
ZA202100717B (en) Antibody molecules that bind pd-l1 and cd137
MY194997A (en) Anti-ccr7 antibody drug conjugates
WO2021173896A8 (en) Materials and methods for modulating an immune response
ZA202007570B (en) Mesothelin and cd137 binding molecules
MX2023002940A (en) Therapeutic b7-h4 binding molecules.
NZ754051A (en) Novel antibodies and uses thereof
AU2020224154A8 (en) Multifunctional molecules that bind to calreticulin and uses thereof
UA95068C2 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
DE602006013029D1 (en) ANTI-EGFR ANTIBODY
WO2022082073A3 (en) Compositions and methods for muc18 targeting
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
SA523441343B1 (en) Multispecific Antibodies Having Specificity for IL-4R and IL-31
MX2010001237A (en) Novel antibodies.
ZA202304787B (en) Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
MX2025003153A (en) Anti-ccr8 antibodies
MX2023007630A (en) Compositions of modified trems and uses thereof.
WO2022232044A3 (en) Anti-clec12a antibodies and uses thereof
MX2022010228A (en) Cd137 binding molecules and uses thereof.
DE60042497D1 (en) ISOLATED NUCLEIC ACID MOLECULES CODING FOR CANCER ASSOCIATED ANTIGENS, THE ANTIGENES PER SE AND THEIR APPLICATIONS
MX2024001328A (en) Novel multi-specific molecules.
MX2009008754A (en) Novel antibodies against igf-ir.
MX2024014265A (en) Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations
MX2024009615A (en) Anti-cd38 binding molecules and uses thereof
WO2020033926A3 (en) Antibodies that bind cd277 and uses thereof